FIELD: medicine; biotechnologies.
SUBSTANCE: anticoagulative antibody is more affinity fixed to FVIIa/TF complex, than to free TF. Discovered is pharmaceutical composition for thrombosis prevention and treatment, containing the described antibody. Offered is method of thrombosis prevention, consisting in introduction of therapeutically effective amount of the described antibody. Furthermore, offered is method of decrease and treatment of deep venous thrombosis (DVT), disseminated intravascular clotting (DIC), acute coronary artery thrombosis or cancer with coagulopathy signs in the patient, consisting that therapeutically effective amount of the described antibody is introduced to the patient. Discovered is method of inflammatory response regulation in the patient, consisting that therapeutically effective amount of the described antibody is introduced to the patient. Polynucleotide sequence encoding the described antibody is presented.
EFFECT: higher efficiency.
24 cl, 10 dwg, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NEW THROMBOMODULINE FUSION PROTEINS PROVIDING DIRECTIONAL TRANSFER TO TISSUE FACTOR AS ANTICOAGULANTS | 2003 |
|
RU2320366C2 |
| MODIFIED FACTOR VII-BASED POLYPEPTIDES AND THEREOF APPLICATION | 2008 |
|
RU2571931C2 |
| MICROVESICLES DERIVED FROM RECOMBINANT YEAST HAVING HAEMOSTATIC ACTIVITIES AND USE THEREOF | 2007 |
|
RU2492184C2 |
| MODIFIED VITAMIN K DEPENDENT POLYPEPTIDES | 2005 |
|
RU2396347C2 |
| DERIVATIVES OF BLOOD COAGULATION FACTORS VII AND VIIA, CONJUGATES AND COMPLEXES CONTAINING THEM AND THEIR APPLICATION | 2012 |
|
RU2620072C2 |
| METHOD FOR PREPARING VITAMIN K-DEPENDENT PROTEINS | 2001 |
|
RU2321633C2 |
| VERSIONS OF GLA DOMAIN OF FACTOR VII OR VIIa | 2004 |
|
RU2373282C2 |
| POLYPEPTYDE OF HEMOSTASIS FACTOR VII, PRODUCTION AND APPLICATION | 2001 |
|
RU2326126C2 |
| ANTIBODIES AGAINST INHIBITOR OF TISSUE FACTOR METABOLIC PATHWAY | 2009 |
|
RU2562114C2 |
| FACTOR VII CHIMERIC MOLECULES | 2010 |
|
RU2563231C2 |
